AKT Selective Cytotoxic Compounds

TECHNICAL FIELD
Therapeutic

APPLICATION
Multiple possible therapies for the treatment of human disease.

DESCRIPTION
Dr. David Plas in collaboration with researchers in the University of Cincinnati's Drug Discovery Center have identified several compounds that enhance cancer cell cytotoxicity in combination with rapamycin. Rapamycin is a compound that has been shown to be effective for chemotherapy of patients with renal cell carcinoma. However, rapamycin has achieved only mixed results in chemotherapy for other solid tumors, in part due to the inappropriate activation of the protein kinase Akt. UC has identified a set of compounds that can compensate for this shortcoming of rapamycin by selectively interfering with Akt-dependent cell survival.

ADVANTAGES
Allows Rapamycin to be used for multiple cancers

INVENTORS
David Plas
Jennifer Barger
William Seibel
Sandra Nelson
Catherine Gallo

STATUS
US Provisional filed

CONTACT
Lynn Briggs
Licensing Associate
lynn.briggs@uc.edu
513-558-3098